Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies
NCT06492304Phase 2Completed
- Sponsor
- CRISPR Therapeutics
- Start
- Aug 2024
- Primary completion
- Mar 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 2
01
Overview
A Phase 2 trial of CTX131 in T-cell lymphoma, B cell lymphoma, acute myeloid leukemia (AML), sponsored by CRISPR Therapeutics. Started Aug 2024; status: completed.
02
Drugs
CTX131
03
Conditions
T-cell lymphomaB cell lymphomaacute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06492304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06492304.